These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 37178414)
61. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes. Xu HH; Wang HL; Xing TJ; Wang XQ Front Immunol; 2022; 13():851622. PubMed ID: 35924232 [TBL] [Abstract][Full Text] [Related]
62. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma. Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y Front Oncol; 2022; 12():876660. PubMed ID: 35747790 [TBL] [Abstract][Full Text] [Related]
63. Investigating the impact of STING pathway activation on breast cancer treatment outcomes: development and validation of a prognostic model. Zhong Y; Cao H; Li W; Deng J; Li D; Deng J Front Immunol; 2024; 15():1438364. PubMed ID: 39185402 [TBL] [Abstract][Full Text] [Related]
64. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer. Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184 [TBL] [Abstract][Full Text] [Related]
65. Development and validation of an eight-gene signature based predictive model to evaluate the prognosis of hepatocellular carcinoma patients: a bioinformatic study. Zhang J; Fu X; Zhang N; Wang W; Liu H; Jia Y; Nie Y Ann Transl Med; 2022 May; 10(9):524. PubMed ID: 35928748 [TBL] [Abstract][Full Text] [Related]
66. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Su Y; Zhang T; Tang J; Zhang L; Fan S; Zhou J; Liang C Front Oncol; 2021; 11():640150. PubMed ID: 33869028 [TBL] [Abstract][Full Text] [Related]
67. Effect of Pyroptosis-Related Genes on the Prognosis of Breast Cancer. Zhou Y; Zheng J; Bai M; Gao Y; Lin N Front Oncol; 2022; 12():948169. PubMed ID: 35957895 [TBL] [Abstract][Full Text] [Related]
68. Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets. Jiang F; Lin H; Yan H; Sun X; Yang J; Dong M Eur J Med Res; 2022 Oct; 27(1):205. PubMed ID: 36253873 [TBL] [Abstract][Full Text] [Related]
69. A six-gene-based signature for breast cancer radiotherapy sensitivity estimation. Chen X; Zheng J; Zhuo ML; Zhang A; You Z Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33179733 [TBL] [Abstract][Full Text] [Related]
70. A pyroptosis-related gene signature predicting survival and tumor immune microenvironment in breast cancer and validation. Gong M; Liu X; Zhao X; Wang H BMC Cancer; 2022 Sep; 22(1):1005. PubMed ID: 36138348 [TBL] [Abstract][Full Text] [Related]
71. Development and validation of a GRGPI model for predicting the prognostic and treatment outcomes in head and neck squamous cell carcinoma. Han F; Wang HZ; Chang MJ; Hu YT; Liang LZ; Li S; Liu F; He PF; Yang XT; Li F Front Oncol; 2022; 12():972215. PubMed ID: 36713509 [TBL] [Abstract][Full Text] [Related]
72. Integrated Bioinformatics Analysis to Identify a Novel Four-Gene Prognostic Model of Breast Cancer and Reveal Its Association with Immune Infiltration. Zhu Y; Luo J; Yang Y Crit Rev Immunol; 2024; 44(2):1-14. PubMed ID: 38305332 [TBL] [Abstract][Full Text] [Related]
73. Establishment and Validation of a Tumor Microenvironment Prognostic Model for Predicting Bladder Cancer Survival Status Based on Integrated Bioinformatics Analyses. Chen Q; Yin G; He X; Jiang T; Zhou H; Wu Y; Li Y Evid Based Complement Alternat Med; 2022; 2022():4351005. PubMed ID: 36225190 [TBL] [Abstract][Full Text] [Related]
74. The nomogram based on the 6-lncRNA model can promote the prognosis prediction of patients with breast invasive carcinoma. Luo D; Yao W; Wang Q; Yang Q; Liu X; Yang Y; Zhang W; Xue D; Ma B Sci Rep; 2021 Oct; 11(1):20863. PubMed ID: 34675301 [TBL] [Abstract][Full Text] [Related]
75. The therapeutic effect and targets of Yuan J; Lin M; Yang S; Yin H; Ouyang S; Xie H; Tang H; Ou X; Zeng Z Heliyon; 2024 May; 10(10):e31137. PubMed ID: 38778969 [TBL] [Abstract][Full Text] [Related]
76. Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinical outcomes and therapeutic responses for breast cancer patients. Shen HY; Xu JL; Zhu Z; Xu HP; Liang MX; Xu D; Chen WQ; Tang JH; Fang Z; Zhang J Neoplasia; 2023 Nov; 45():100942. PubMed ID: 37839160 [TBL] [Abstract][Full Text] [Related]
77. Construction and validation of chemoresistance-associated tumor- infiltrating exhausted-like CD8+ T cell signature in breast cancer: cr-TILCD8TSig. Cai DQ; Cai D; Zou Y; Chen X; Jian Z; Shi M; Lin Y; Chen J Front Immunol; 2023; 14():1120886. PubMed ID: 36949939 [TBL] [Abstract][Full Text] [Related]
78. Identification and validation of an m6A-related gene signature to predict prognosis and evaluate immune features of breast cancer. Li W; Wang X; Li C; Chen T; Zhou X; Li Z; Yang Q Hum Cell; 2023 Jan; 36(1):393-408. PubMed ID: 36403174 [TBL] [Abstract][Full Text] [Related]
79. Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis. Zhang P; Li J; Wang Z; Zhao L; Qiu J; Xu Y; Wu G; Xia Q Front Oncol; 2023; 13():1077309. PubMed ID: 36969076 [TBL] [Abstract][Full Text] [Related]
80. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]